COPD
Out line
What is COPD?
Overview
Causes of COPD
Symptoms of COPD
What's the difference between COPD and asthma?
Diagnostic tests needed for COPD
Medical management of COPD
Preventive measures
Nursing intervention
Outlook and Prognosis
It is unclear if different types of COPD exist. While
previously divided into emphysema & chronic
bronchitis, emphysema is only a description of lung
changes rather than a disease itself, & chronic
bronchitis is simply a descriptor of symptoms that may
or may not occur with COPD
Difference between COPD and Asthma
InCOPDthereispermanentdamagetotheairways.The
narrowedairwaysarefixed,&sosymptomsarechronic
(persistent).R
xtoopenuptheairways,istherefore
limited.
Inasthmathereisinflammationintheairwayswhich
makesthemusclesintheairwaysconstrict.Thiscauses
theairwaystonarrow.Thesymptomstendtocome&go,
&varyinseverityfromtimetotime.R
xtoreduce
inflammation&toopenuptheairwaysusuallyworks
well.
COPDismorelikelythanasthmatocauseachronic
(ongoing)coughwithsputum.
Nighttimewakingwithbreathlessnessorwheezeis
commoninasthmaanduncommoninCOPD.
COPDisrarebeforetheageof35whilstasthmais
commoninunder-35.
Difference between COPD and Asthma
COPD is a type of obstructive lung disease in which
chronic incompletely reversible poor airflow (airflow
limitation) & inability to breathe out fully (air trapping)
exist.
The poor airflow is the result of breakdown of lung
tissue (known as emphysema) & small airways
disease known as obstructive bronchiolitis.
The relative contributions of these 2 factors vary
between people. Severe destruction of small airways
can lead to the formation of large air pockets—
known as bullae—that replace lung tissue. This form
of disease is called bullous emphysema
Emphysema
In emphysema, impaired gas exchange
(oxygen, carbon dioxide) results from
destruction of the walls of overdistended
alveoli.
“Emphysema” is a pathological term that
describes an abnormal distention of the air
spaces beyond the terminal bronchioles,
with destruction of the walls of the alveoli.
It is the end stage of a process that has
progressed slowly for many years.
Emphysema
As the walls of the alveoli are destroyed (a process
accelerated by recurrent infections), the alveolar
surface area in direct contact with the pulmonary
capillaries continually decreases, causing an increase in
dead space (lung area where no gas exchange can
occur) and impaired oxygen diffusion, which leads to
hypoxemia.
In the later stages of the disease, carbon
dioxide elimination is impaired, resulting in
increased carbon dioxide tension in arterial
blood (hypercapnia) and causing respiratory
acidosis.
Emphysema
As the alveolar walls continue to break down, the
pulmonary capillary bed is reduced.
Consequently, pulmonary blood flow is increased,
forcing the right ventricle to maintain a higher blood
pressure in the pulmonary artery.
Hypoxemia may further increase pulmonary artery
pressure.
Thus, right-sided heart failure (cor pulmonale) is one of
the complications of emphysema. Congestion,
dependent edema, distended neck veins, or pain in the
region of the liver suggests the development of cardiac
failure.
Risk Factors
COPD/Emphysema
Exposure to tobacco smoke accounts for an
estimated 80% to 90% of COPD cases
Passive smoking
Occupational exposure
Ambient air pollution
Genetic abnormalities, including a
deficiency of alpha1-antitrypsin, an enzyme
inhibitor that normally counteracts the
destruction of lung tissue by certain other
enzymes
Clinical Manifestations
COPD is characterized by three primary
symptoms: cough, sputum production, and
dyspnea on exertion.
These symptoms often worsen over time.
Chronic cough and sputum production often
precede the development of airflow limitation
by many years.
However, not all individuals with cough and
sputum production will develop COPD.
Dyspnea may be severe and often interferes
with the patient’s activities.
Clinical Manifestations
Weight loss is common because dyspnea
interferes with eating, and the work of
breathing is energy-depleting.
Often the patient cannot participate in even
mild exercise because of dyspnea; as COPD
progresses, dyspnea occurs even at rest.
Clinical Manifestations
As the work of breathing increases over
time, the accessory muscles are recruited
in an effort to breathe.
The patient with COPD is at risk for
respiratory insufficiency and respiratory
infections, which in turn increase the risk
for acute and chronic respiratory failure.
Clinical Manifestations
In COPD patients with a primary
emphysematous component, chronic
hyperinflation leads to the “barrel chest”
thorax configuration.
This results from fixation of the ribs in the
inspiratory position (due to hyperinflation) and
from loss of lung elasticity (Fig. 24-3).
Retraction of the supraclavicular fossae
occurs on inspiration, causing the shoulders
to heave upward (Fig. 24-4). In advanced
emphysema, the abdominal muscles also
contract on inspiration.
Assessment and Diagnostic Findings
The nurse should obtain a thorough health
history for a patient with known or potential
COPD.
Pulmonary function studies are used to help
confirm the diagnosis of COPD, determine
disease severity, and follow disease
progression.
Spirometry is used to evaluate airflow
obstruction, which is determined by the ratio
of FEV1 (volume of air that the patient can
forcibly exhale in 1 second) to forced vital
capacity (FVC).
Complications
Respiratory insufficiency and
Respiratory failure are major life-
threatening complications of COPD.
Medical Management
RISK REDUCTION
Smoking cessation is the single most effective
intervention to prevent COPD or slow its progression.
Recent surveys indicate that 25% of all American
adults smoke.
Nurses play a key role in promoting smoking
cessation and educating patients about ways to do
so.
Patients diagnosed with COPD who continue to
smoke must be encouraged and assisted to quit.
Medical Management
PHARMACOLOGIC THERAPY
Bronchodilators: relieve bronchospasm
and reduce airway obstruction by allowing
increased oxygen distribution throughout the
lungs and improving alveolar ventilation.
Corticosteroids: Inhaled and systemic
corticosteroids (oral or intravenous) may
also be used in COPD but are used more
frequently in asthma.
MANAGEMENT OF
EXACERBATION
An exacerbation of COPD is difficult to
diagnose, but signs and symptoms may
include increased dyspnea, increased
sputum production and purulence,
respiratory failure, changes in mental
status, or worsening blood gas
abnormalities.
Primary causes for an acute exacerbation
include tracheobronchial infection and air
pollution.
MANAGEMENT OF
EXACERBATION
Secondary causes are pneumonia;
pulmonary embolism; pneumothorax; rib
fractures or chest trauma; inappropriate use
of sedative, opioid, or beta-blocking agents;
and right-or left-sided heart failure.
First, the primary cause of the exacerbation
is identified, and then specific treatment is
administered.
MANAGEMENT OF
EXACERBATION
Optimization of bronchodilator medications
is the first-line therapy and involves
identifying the best medication or
combinations of medications taken on a
regular schedule for that patient.
Depending on the signs and symptoms,
corticosteroids, antibiotic agents, oxygen
therapy, and intensive respiratory
interventions may also be used.
OXYGEN THERAPY
Oxygen therapy can be administered as long-term
continuous therapy, during exercise, or to prevent
acute dyspnea.
Long-term oxygen therapy has been shown to
improve the patient’s quality of life and survival.
Indications for oxygen supplementation include a
PaO2 of 55 mm Hg or less or evidence of tissue
hypoxia and organ damage such as cor pulmonale,
secondary polycythemia, edema from right heart
failure, or impaired mental status.
NURSING ALERT
Because hypoxemia stimulates respiration in the
patient with severe COPD, increasing the oxygen flow
to a high rate may greatly raise the patient’s blood
oxygen level.
At the same time, this will suppress the respiratory
drive, causing increased retention of carbon dioxide
and CO2 narcosis.
The nurse should closely monitor the patient’s
respiratory response to oxygen administration via
physical assessment, pulse oximetry, and/or arterial
blood gases.
SURGICAL MANAGEMENT
Bullectomy: is a surgical option for select patients
with bullous emphysema. Bullae are enlarged
airspaces that do not contribute to ventilation but
occupy space in the thorax; these areas may be
surgically excised.
Lung Volume Reduction Surgery: Treatment options
for patients with end-stage COPD with a primary
emphysematous component are limited, although lung
volume reduction surgery is an option for a specific
subset of patients.
Lung Transplantation:is a viable alternative for
definitive surgical treatment of end-stage emphysema.
A lateral chest x-ray of a person
with emphysema. Note the barrel
chest and flat diaphragm
Chest X-ray demonstrating severe
COPD. Note the small heart size
in comparison to the lungs.
Axial CT image of the lung of a
person with end-stage bullous
emphysema.
A severe case of bullous
emphysema
Lung bulla as seen on CXR in
a person with severe COPD
COPD
Medical management (cont…)
Stop smoking
Oxygenation with low concentration during the acute
episodes
Inasthma adrenaline ( epinephrine) SC if the
bronchospasm not relieved.
Aminophylins IV if the above treatment does not help.
IVcorticosteroids for patients with chronic asthma or
frequent attack.
Sedative or tranquilizers to calm the patient.
Increase fluids intake to correct loss of diaphoresis &
inaccessible loss of hyperventilation.
Intubations & mechanical ventilation if there is
respiratory failure.